Ocean Biomedical, INC 8-K filings

Ocean Biomedical, Inc. announced Nasdaq's final decision to delist its common stock and warrants, alongside the resignations of its CFO and a director.

Ocean Biomedical, Inc. has received a final decision from the Nasdaq Listing and Hearing Review Council affirming its delisting from The Nasdaq Stock Market.

Ocean Biomedical, Inc. announced the immediate termination of its material licenses by Elkurt, Inc. following a failure to cure contractual breaches within the stipulated 30-day period.

Ocean Biomedical, Inc. has received notice from Elkurt, Inc. terminating multiple core technology license agreements due to alleged material breaches, including over $612,000 in unpaid fees, failure to pay patent costs, and a lack of diligent product development and milestone achievement.

Ocean Biomedical faces delisting from Nasdaq and announces a strategic shift into power infrastructure and cryptocurrency investments to bolster its financial position.

Ocean Biomedical held its annual meeting of stockholders on March 28, 2025, and approved several proposals, including the election of directors and a reverse stock split.

Ocean Biomedical has irrevocably lowered the conversion price of a promissory note from $1.50 to $0.01 per share for a $400,000 conversion amount.

Ocean Biomedical received a notice from Nasdaq regarding non-compliance with listing rules due to its stock price falling below $0.10 for ten consecutive trading days.

Amy Griffith resigns from Ocean Biomedical's Board of Directors, effective as of the next Annual Meeting, prompting a search for new independent directors.

Ocean Biomedical, Inc. announces a private placement of Series A redeemable convertible preferred stock to raise up to $450,000, primarily aimed at facilitating a reverse stock split.

Ocean Biomedical, Inc. amended its bylaws on February 14, 2025, to change the quorum requirement for shareholder meetings to one-third of outstanding common stock.

Ocean Biomedical, Inc. reports having 132,163,312 shares of common stock issued and outstanding as of February 11, 2025.

Ocean Biomedical received a notice from Nasdaq regarding non-compliance with listing rules due to the delay in holding its annual shareholder meeting.

Ocean Biomedical has appointed Berkowitz Pollack Brant as its new independent registered public accounting firm, effective December 17, 2024.

Ocean Biomedical has received a notice from Nasdaq for failing to maintain the minimum market value of listed securities, triggering a 180-day compliance period.

Ocean Biomedical received a notice from Nasdaq for failing to maintain a minimum share price of $1, triggering a 180-day compliance period.

Ocean Biomedical has dismissed Deloitte & Touche as its independent registered public accounting firm, effective December 2, 2024, due to a board decision, not due to any disagreements.

Ocean Biomedical has received a notice from Nasdaq regarding its failure to file its quarterly report, adding to previous delisting concerns due to late annual and quarterly filings.

Ocean Biomedical has appointed M. Michelle Berrey as Interim CEO, effective immediately, after Elizabeth Ng announced a sabbatical for personal reasons.

Ocean Biomedical has received a delisting notice from Nasdaq due to its failure to file required financial reports, and the company plans to appeal the decision.

Ocean Biomedical has increased its ownership in Virion Therapeutics to 22% by revising an existing agreement, involving a combination of cash and potential equity contributions.

Ocean Biomedical received a notice from Nasdaq for failing to file its quarterly report, putting the company at risk of delisting if compliance is not regained.

Ocean Biomedical has secured up to $7.675 million in additional funding, restructured existing debt, and amended earnout agreements, addressing past defaults and setting the stage for future financial stability.

Ocean Biomedical has received a notice from Nasdaq for failing to file its quarterly report on time, putting the company at risk of potential delisting.

Ocean Biomedical has received a notice from Nasdaq for failing to file its annual report on time, placing the company in non-compliance with listing rules.

Ocean Biomedical has appointed Amy Griffith, a seasoned government relations and public affairs executive, to its board of directors, effective March 4, 2024.

Ocean Biomedical has appointed Jolie Kahn as its new Chief Financial Officer, effective March 1, 2024, replacing Gurinder Kalra who resigned on January 30, 2024.

Ocean Biomedical has received a notification from Nasdaq that its market value of listed securities has fallen below the required $35 million minimum, placing it at risk of delisting.

Ocean Biomedical has received a notification from Nasdaq for not meeting the minimum bid price requirement, placing its listing status at risk.